Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Planning Pivotal MyoCell Trial, Bioheart Files For $35M IPO

Feb. 15, 2007

By Jennifer Boggs

Planning Pivotal MyoCell Trial, Bioheart Files For $35M IPO

Feb. 15, 2007

By Jennifer Boggs

Pharmacopeia Gets $15M Up Front In Organon Deal

Feb. 14, 2007

By Jennifer Boggs

Pharmacopeia Gets $15M Up Front In Organon Deal

Feb. 14, 2007

By Jennifer Boggs

Onyx Skyrockets On Phase III Nexavar Data In Liver Cancer

Feb. 13, 2007

By Jennifer Boggs

Shares of Onyx Pharmaceuticals Inc. soared more than 95 percent on news that its kidney cancer drug, Nexavar, yielded positive survival data in a Phase III trial in liver cancer patients. (BioWorld Today)

Onyx Skyrockets On Phase III Nexavar Data In Liver Cancer

Feb. 13, 2007

By Jennifer Boggs

Shares of Onyx Pharmaceuticals Inc. soared more than 95 percent on news that its kidney cancer drug, Nexavar, yielded positive survival data in a Phase III trial in liver cancer patients. (BioWorld Today)

QLT and Subsidiary Settle Patent Infringement Suit

Feb. 12, 2007

By Jennifer Boggs

Targanta's $70M Series C To Fund Oritavancin NDA, Trials

Feb. 12, 2007

By Jennifer Boggs

Targanta's $70M Series C To Fund Oritavancin NDA, Trials

Feb. 12, 2007

By Jennifer Boggs

QLT and Subsidiary Settle Patent Infringement Suit

Feb. 12, 2007

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.